Iovance Biotherapeutics Inc. (IOVA) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Iovance Biotherapeutics Inc. (IOVA) dropped -35.45% to $9.56 as options desks priced 38% call premium vs. 62% put protection around the $9 max-pain magnet. Solid 34% profit margin (-35% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Key TakeawaysIovance shares fell another 11% today after Baird cut its price target to $9 from $11, a day after a 35% drop on updated lung cancer data. The trial’s 24.
Iovance Biotherapeutics (NasdaqGM: IOVA) reported updated positive Phase 2 lifileucel data in metastatic non-small cell lung cancer. A biomarker-enriched subgroup of mNSCLC patients showed a high response rate to lifileu
Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.
Insmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.
For questions about this article or underlying research, email help@trefis.com.
Virginia Retirement Systems raised its stakes in all three stocks, with combined holdings worth nearly $3 million at September-end.
Illumina (ILMN) delivered earnings and revenue surprises of +5.88% and -0.76%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
US session market movers: NUBURU led gainers at 125.0% while GameStop's GME.W fell 48.11% among the biggest losers.
These biotechs’ valuations are through the roof.
Iovance stock crashed Thursday, undercutting its 50-day line, on new durability questions for its experimental lung cancer treatment.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +60.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IOVA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IOVA. Explore sector supply chains on /butterfly.
Why IOVA Stock dropped -35.45% Today — RQD Quant Desk Flash. Solid 34% profit margin (-35% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.